← Back to dossier
Patient handout

Neonatal hyperbilirubinemia — kernicterus prevention (AAP 2022 thresholds)

PRODUCTION

1. Your condition

This handout is for neonatal hyperbilirubinemia — kernicterus prevention (aap 2022 thresholds). Your care team identified this based on: visible jaundice in neonate ≥ 35 wk ga — screening tsb or tcb indicated (kemper aap 2022 pmid 35927462).

Other reasons your team may use this plan: universal pre-discharge bilirubin screening — tsb or tcb at discharge or by 24-48 h of life (kemper aap 2022 strong recommendation); tsb at or above aap 2022 figure 2 phototherapy curve for ga + hours-age + risk factors (kemper aap 2022); tsb at or above aap 2022 figure 3 exchange-transfusion curve — emergent (kemper aap 2022).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
phototherapy_standard_or_intensiveStandard: 8-10 µW/cm²/nm at 460-490 nm blue light; Intensive: ≥ 30 µW/cm²/nm with multiple light banks + minimal swaddlingtransdermal_phototherapycontinuous with breaks for feeding only if standard; uninterrupted if intensive near exchangeMechanism: 460-490 nm blue light isomerizes bilirubin to water-soluble lumirubin excreted in bile/urine; intensive reduces TSB ~ 0.5-1 mg/dL per hour (Kemper AAP 2022)
ivig0.5-1 g/kg IV over 2-4 h; may repeat in 12 h if no responseIVone dose, repeat at 12 h if no responseSaturates Fc receptors on reticuloendothelial macrophages, reducing antibody-coated RBC destruction in isoimmune hemolytic disease (Rh, ABO); reduces need for exchange transfusion per Cochrane + AAP 2022
exchange_transfusion_double_volumeDouble-volume exchange = 160 mL/kg via central / umbilical venous catheter (UVC); typically using reconstituted whole blood (RBC + FFP), irradiated, CMV-seronegative, < 7 d oldcentral_venous_catheter_UVC_or_centralone procedure; repeat if TSB rebounds back above exchange thresholdRemoves ~ 85% of circulating bilirubin + ~ 25-50% of extravascular bilirubin; corrects anemia in isoimmune; emergent procedure for ABE or TSB above exchange curve (Kemper AAP 2022)
enteral_feeding_supplementationSupplemental expressed breast milk OR formula per lactation consult; reassess weight + urine output + serum sodiumenteral_PO_or_NGafter every 2-3 h BF attempt or per lactation planReduces enterohepatic recirculation of bilirubin; corrects dehydration; AAP 2022 BF + intake assessment recommendation
iv_fluids_maintenance_or_resuscitationD10W or D10NS at maintenance (4-2-1 rule by weight) if dehydrated or NPO; resuscitation 10-20 mL/kg NS slowly if hypotensive (neonatal-specific slower bolus rate)IVcontinuousCorrect dehydration; phototherapy increases insensible water loss 10-20%; sepsis-associated shock requires fluid resuscitation per AAP/PALS neonatal-adapted

Plan: Neonatal hyperbilirubinemia — by AAP 2022 threshold zone (Kemper PMID 35927462)

3. When to call your provider

Contact your care team if any of the following happen:

  • TSB rising despite home phototherapy OR not falling at expected rate → admission for intensive phototherapy + reassessment
  • Worsening jaundice + lethargy + poor feeding + arching → emergent ED return; ABE rule-out + exchange-transfusion preparation
  • Conjugated component emerging at > 2 wk (jaundice persists) → peds-GI/hepatology referral + biliary atresia rule-out by 4 wk (Kasai outcomes time-sensitive)
  • Hearing loss confirmed on audiology → ENT + audiology + speech + early intervention
  • Neurodevelopmental delay confirmed → developmental peds + PT/OT/speech
  • G6PD-positive infant with hemolytic crisis after trigger exposure → ED + transfusion + ID consult

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • ABE neurologic features — lethargy + poor feeding + hypotonia OR hypertonia + opisthotonus + retrocollis + high-pitched cry — life-threatening pre-kernicterus phase; emergent exchange transfusion + ICU + neuro consult; reversible if caught early (Watchko & Tiribelli NEJM 2013; Kemper AAP 2022)(life-threatening)
  • TSB at or above AAP 2022 Figure 3 exchange-transfusion curve for gestational age + hours of age + risk factors — life-threatening; emergent exchange + intensive phototherapy + hematology + IVIG if isoimmune (Kemper AAP 2022 PMID 35927462)(life-threatening)
  • Isoimmune hemolytic disease — DAT (Coombs) positive + maternal-infant ABO or Rh mismatch + rising bilirubin → IVIG 0.5-1 g/kg + intensive phototherapy + close monitoring; exchange if continued rise (Kemper AAP 2022; Cochrane IVIG reviews)
  • G6PD deficiency identified in infant requiring phototherapy — AAP 2022 universal G6PD testing recommendation (broader than 2004 history-based criterion); treat aggressively; consider IVIG if also isoimmune; avoid offending meds (sulfa, nitrofurantoin, primaquine, methylene blue) and counsel on fava-bean avoidance (Kemper AAP 2022)
  • Preterm < 35 wk GA — AAP 2022 explicitly excludes < 35 wk from its phototherapy + exchange curves; lower thresholds appropriate but case-by-case + hematology consult; separate AAP statement for preterm pending (Kemper AAP 2022 scope caveat)
  • Exclusive BF + > 10% weight loss + low urine output + jaundice triad — supplement (expressed breast milk or formula per lactation plan); lactation consult; reassess weight + urine output + serum sodium (hypernatremic dehydration risk) (Kemper AAP 2022 BF assessment)
  • TSB rising despite home phototherapy OR not falling at expected rate → admission for intensive phototherapy + reassessment; rule out hemolysis (DAT, G6PD, retic) + sepsis features (Kemper AAP 2022; Maisels CMAJ 2015)
  • Late preterm 35-36 wk GA + exclusive breastfeeding + early discharge → higher kernicterus risk; closer follow-up — 24 h reassessment + Bhutani-zone tracking + lactation consult (Bhutani 1999 percentile risk + Kemper AAP 2022 late-preterm caveat)

5. Follow-up

Outpatient peds within 24-48 h of discharge for all phototherapy-treated infants + all high-risk (Bhutani high-intermediate/high percentile) + late preterm 35-36 wk + exclusive BF cohorts. Rebound TSB check at 12-24 h post-phototherapy discontinuation if elevated risk. G6PD-positive infant: long-term outpatient counseling on trigger-medication avoidance (sulfa drugs, nitrofurantoin, primaquine, methylene blue, fava beans). Lactation support continued + weight + feeding monitoring. Universal parental kernicterus-prevention education at every visit (jaundice warning signs, when to seek evaluation). Neurodevelopmental screening at 6-12 mo if kernicterus risk factors (any ABE features, TSB approached exchange, prolonged severe hyperbilirubinemia) — Bayley III or ASQ-3; hearing screen (AABR — sensorineural hearing loss is a kernicterus sequela). Audiology referral if hearing screen abnormal.

6. Sources

Guideline: Kemper KJ et al — AAP 2022 Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation — Pediatrics 2022 (PMID 35927462) — substantially revised 2004 thresholds; introduced escalation-of-care concept; universal G6PD testing in all infants requiring phototherapy; universal pre-discharge screening + Bhutani 1999 nomogram (PMID 9917432). Cross-references: Watchko & Tiribelli NEJM 2013 (kernicterus pathophysiology + ABE-kernicterus spectrum); Maisels CMAJ 2015 (operational review including home phototherapy); NICE NG98 (UK parallel guideline); Kimberlin Red Book 2021 (neonatal HSV cross-ref for conjugated hyperbilirubinemia with hepatitis).

  1. pubmed.ncbi.nlm.nih.gov/35927462
  2. pubmed.ncbi.nlm.nih.gov/35927519
  3. pubmed.ncbi.nlm.nih.gov/9917432